Keep the value case connected to what happened
An opportunity becomes commercially useful when the people responsible can understand what it would require, who benefits and whether the result justifies the effort. The original estimate is only part of that account.
NEUVIOR’s value-assurance direction within PHARMORIS connects a medicines case with implementation, resource use and subsequent review. The aim is to help pharmacy, operational and financial colleagues examine the same proposition in terms that support a real decision.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Agree what the figure is meant to describe
A potential opportunity, a budget movement, a change in expenditure and a realised benefit describe different things. So do staff capacity and cash. A pharmacy owner, hospital finance leader and service manager may need different measures from the same programme.
Define the period, scope and comparison before presenting a headline. Identify whose resources are counted and which costs sit outside the immediate team. This helps people understand what the estimate can support and prevents a promising figure from carrying more meaning than the underlying analysis allows.
Use a baseline the organisation recognises
The starting position needs to reflect competent existing practice. What activity takes place today? Which staff effort is required? Which costs are fixed, variable or shared? What would happen if the proposed change were not introduced?
National prescribing or expenditure data can provide context, but a local business case needs information that fits its question. A national average may conceal differences in service mix, demand or operating arrangements. Agreeing the baseline with the relevant teams makes the comparison more useful and exposes assumptions worth checking before resources are committed.
Count the cost of introducing the change
A new approach may require onboarding, training, checking, coordination, software, support and ongoing review. Some work is carried by the supplier; some falls on the organisation adopting the change. Both affect its usefulness.
For a pharmacy group introducing a service, additional activity may create income and new operating demands together. For a provider, released professional time may increase capacity without reducing payroll expenditure. A strong case explains these effects separately. It also considers how the economics change with scale, rather than assume that every additional site will be equally easy to support.
Make the important assumptions visible
An estimate can depend on participation, the speed of introduction, professional capacity, price or the proportion of work that can appropriately change. Those assumptions should be understandable to the person asked to rely on them.
Examine which inputs most affect the result. What if uptake is slower, checking takes longer or support is more intensive than expected? A range with a clear basis can be more decision-useful than an exact-looking figure. The aim is to identify which evidence would strengthen the case and which condition would make proceeding unattractive.
The denominator changes the story.
England’s medicinal dispensing groups do not rank in the same order by item count and net ingredient cost. Inspecting both measures gives a different view of the public data.
That difference helps formulate a question. It does not establish a local saving: acquisition terms, the actual comparator and implementation effort still need their own evidence.
Image source and contextNEUVIOR analysis of NHSBSA England PCA 2025/26 medicinal chapters 01–15. NIC is not acquisition price, local savings, revenue or addressable market.
The leaders change
with the measure.
England’s 2025/26 medicinal dispensing data. Compare the most dispensed groups with the highest net ingredient-cost groups.
0 of 10 groups appear in both lists.
Atorvastatin
- Prescription items
- 78,042,8716.3% of medicinal items
- Net ingredient cost
- £73,573,6380.74% of medicinal NIC
- National ranks
- 1 by items · 25 by NIC
A different ranking suggests a different question. It does not establish what a particular organisation pays or what a proposed change would save.
NHSBSA (2026), Chemical_Substances worksheet, row 266. Code 0212000B0. NEUVIOR analysis of medicinal BNF chapters 01–15, England, 1 April 2025–31 March 2026.
Read the method and scope
Item and NIC lists are ranked separately using exact item counts and integer-pence cost, with ties ordered by BNF code. The selected lists can contain different groups. The denominators remain 1,239,249,027 medicinal items and £9,983,762,289 medicinal NIC, rather than the full dispensing total. NIC is an ingredient-cost measure, not an acquisition price, reimbursement, revenue or an addressable-market estimate.
The workbook was published on 4 June 2026; the local source snapshot was verified on 13 October 2026. This is a dated public-data analysis, not a live feed. Contains public sector information licensed under the Open Government Licence v3.0.
Inspect the complete analysisDownload the source-derived rows
Return to the original case
A subsequent review should explain what was introduced, which resources were used and what changed. Keep the original assumptions visible so that the team can distinguish a forecasting error from incomplete implementation or a change in external conditions.
This is useful even when the expected benefit does not appear. The organisation can identify whether to adapt the approach, narrow its use or stop. Preserve the distinction between an observed financial effect and an outcome that requires further investigation. A completed task or favourable trend alone does not establish that the programme caused a benefit.
Build an evaluation that a buyer can use
Our planned value work would examine clarity of definitions, completeness of costs, ease of reconstructing the case and the effort required to keep the record useful. Financial-return claims need an appropriate comparison and evidence for the setting in which they are made.
The strongest result helps a budget holder decide what to do next. A pharmacy owner needs a service it can sustain. A hospital or system leader needs a defensible account of resources and implementation. An investor needs to understand the buyer, recurring value and cost of serving that buyer.
Bring a value question with a real decision behind it
Tell us the proposed change, who pays, who receives the benefit and which evidence currently informs the case. Include the approach you use today and the decision a better comparison would support.
That gives a PHARMORIS discussion a useful centre: an evaluation that can clarify whether the opportunity is worth pursuing and what it would take to deliver it.